5-hydroxymethylcytosine has been researched along with Cystadenocarcinoma, Serous in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dinulescu, DM; Getchell, CR; Gupta, M; Hasselblatt, KT; Hirsch, MS; Kaplan, SJ; Ko, JY; Lee, JJ; Li, W; Lian, CG; Liu, JF; MacDonald, LA; Malik, A; Matulonis, UA; McCarthy, ET; Medina, JE; Murphy, GF; Ohman, AW; Sasamoto, N; Shafrir, A; Terry, KL; Tucker, DW; Xu, S; Zhang, H | 1 |
1 other study(ies) available for 5-hydroxymethylcytosine and Cystadenocarcinoma, Serous
| Article | Year |
|---|---|
Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer.
Topics: 5-Methylcytosine; Animals; Cell Survival; Cellular Reprogramming; Combined Modality Therapy; Cystadenocarcinoma, Serous; Dioxygenases; Disease Models, Animal; Disease Progression; DNA Methylation; DNA-Binding Proteins; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Grading; Ovarian Neoplasms; Prognosis; Proto-Oncogene Proteins; Recurrence; Survival Analysis; Xenograft Model Antitumor Assays | 2018 |